2006 Symposium: Retinal Degeneration, Understanding the Causes and Finding the Cures
Download pdf of Brochure and Registration Application
Monday, July 31, 2006
Registration Reception
5:00-8:00pm Regisration
Tuesday, August 1, 2006
Registration & Breakfast
7:00-8:00am Continental Breakfast
7:00-9:00am Registration, for those who didn't register on Monday
Meeting Introductions
8:00-8:15am Introduction by Raymond Lund, PhD, Univ. of Utah, John A. Moran Eye Center
8:15-8:30am Overview: Alan Bird, MD, Univ. College, London, Institute of Ophthalmology
The Normal Retina
8:30-8:45am Introduction by Helga Kolb, PhD, Univ. of Utah, John A. Moran Eye Center
8:45-9:20am Heinz Wässle, PhD, Max-Planck-Institute for Brain Research, Dept. of Neuroanatomy
9:20-9:55am Richard Masland, PhD, Massachusetts General Hospital, Howard Hughes Medical Institute
9:55-10:10am Break
10:10-10:45am Monica Vetter, PhD, Univ. of Utah, Dept. of Neurobiology & Anatomy
10:45-11:30am Session Discussion including Helga Kolb, Heinz Wassle, Richard Masland, Monica Vetter
The Injured Retina
11:30-11:45am Introduction by Wolfgang Baehr, PhD, Univ. of Utah, John A. Moran Eye Center
11:45am-12:20pm Amir Rattner, PhD, Johns Hopkins Medical School, Dept. of Molecular Biology and Genetics
12:20-1:20pm Lunch
1:20-1:55pm Dean Bok, PhD, UCLA, Jules Stein Eye Institute
1:55-2:30pm Robert Marc, PhD, Univ. of Utah, John A. Moran Eye Center
2:30-3:05pm Steven Fisher, PhD, UCSB, Neuroscience Research Institute
3:05-3:20pm Break
3:20-4:05pm Session Discussion including Wolfgang Baehr, Amir Rattner, Dean Bok, Robert Marc, Steven Fisher
Rescue & Replacement
4:05-4:20pm Introduction by Edward Levine, PhD, Univ. of Utah, John A. Moran Eye Center
4:20-4:55pm William Hauswirth, PhD, Univ. of Florida, Dept. of Ophthalmology
4:55-5:30pm Joe Rizzo, Massachusetts Eye & Ear Infirmary, Dept. of Ophthalmology
Wednesday, August 2, 2006
7:00-8:00am Continental Breakfast
Rescue & Replacement (continued)
8:00-8:35am Gustavo Aguirre, VME, PhD, PhD(hc), Univ. of Pennsylvania, School of Veterinary Medicine
8:35-9:10am Matthew LaVail, PhD, UCSF, Dept. of Ophthalmology
9:10-9:45am Raymond Lund, PhD, Univ. of Utah, John A. Moran Eye Center
9:45-10:20am Thomas Reh, PhD, Univ. of Washington, Dept. of Neurobiology & Behavior
10:20-10:35am Break
10:35-11:10am Paul Sieving, MD, PhD, National Institute of Health, National Eye Institute
11:10-11:55am Session Discussion including Edward Levine, William Hauswirth, Joe Rizzo, Gustavo Aguirre, Matthew LaVail, Raymond Lund, Thomas Reh, Paul Sieving
11:55am-12:55pm Lunch
Clinical Treatments
12:55-1:10pm Introduction by Paul Bernstein, MD, PhD, Univ. of Utah, John A. Moran Eye Center
1:10am-1:45pm Eric Pierce, MD, PhD, Univ. of Pennsylvania, FM Kirby Center for Molecular Ophthalmology
1:45-2:20pm Kang Zhang, MD, PhD, Univ. of Utah, John A. Moran Eye Center
2:20-2:55pm Gregory Hageman, PhD, Univ. of Iowa, Dept. of Ophthalmology
2:55-3:30pm Paul Bernstein, MD, PhD, Univ. of Utah, John A. Moran Eye Center
3:30-3:45pm Break
3:45-4:20pm Peter Campochiaro, MD, Johns Hopkins Medical School, Dept. of Ophthalmology
4:20-4:55pm Mark Humayun, MD, Doheny Eye Institute, Retina Institute
4:55-5:40pm Session Discussion including Paul Bernstein, Eric Pierce, Kang Zhang, Gregory Hageman, Peter Campochiaro, Mark Humayun
Thursday, August 3, 2006
Grand Opening of New Moran, Poster Sessions, Building Tours
9:00-10:30am Grand Opening Ceremonies
11:00am-1:00pm Poster Sessions & Building Tours
1:00-2:00am Lunch
Translational Research and the Patient
2:00-2:15pm Introduction by Randall Olson, MD, Univ. of Utah, John A. Moran Eye Center
2:15-2:30pm Alan Bird, MD, Univ. College, London, Institute of Ophthalmology
2:30-2:45pm Carmen Puliafito, MD, Univ. of Miami, Bascom Palmer Eye Institute, McKnight Research Center
2:45-3:00pm Jon Huntsman, Jr., Utah Governor
3:00-3:15pm Julian Gangolli, Allergan
3:15-3:30pm Stephen Rose, PhD, Foundation Fighting Blindness, Science Dept.
3:30-3:45pm Break
3:45-4:45pm Roundtable Discussion including Randall Olson, Alan Bird, Carmen Puliafito, Jon Huntsman, Julian Gangolli, Stephen Rose
About the Symposium
Retinal degenerative diseases such as retinitis pigmentosa, age related macular degeneration and related diseases afflict millions of people world-wide. Until recently they have eluded treatments. Now laboratory research has developed a range of approaches that can slow the progress of the diseases or reverse their course.
Such approaches have evolved from an intimate understanding of the organization of the normal retina, knowledge of how the retina may be affected by degenerative events, and by probing the mechanisms that lead to degenerative changes. These factors have led to current and envisioned approaches to clinical application, including dietary management, containment of the vascular changes that accompany advanced age related macular degeneration, growth factor delivery, gene therapy, cell-based therapies and retinal cell replacement by biological and non-biological approaches. Depending on the treatment, as we translate the research to clinic, many new difficulties must be overcome.
The purpose of this symposium is to bring together leaders who are engaged in understanding the normal and diseased retina and in specific endeavors to translate retinal research to clinical applications. We want to provide a realistic and up-to-date evaluation of current progress toward treatment of retinal disease.
With this in mind, there will be opportunities to have extended discussions around each of the topics covered. We hope the comfortable surroundings with a smaller group and the atmosphere provided by the new building, will produce an innovative event with synergistic discoveries and strong alliances.
With this type of event, it is possible to have schedule changes. The Moran Eye Center reserves the right to alter this schedule.
Poster Sessions
We invite participants to contribute to the poster session, if desired. The poster session layout will follow the same format used by ARVO. Contact Julee LaMothe if you would like to present at 801-585-3723.
Location
Salt Lake City combines the amenities of a major metropolitan area with the friendliness of a small, western city. Hosting the Olympic Winter Games of 2002 enhanced the community's profile as a world-class travel destination. In addition to offering first class accommodations, fine dining, noted attractions, historic sites, and great shopping, Salt Lake is nestled in a valley at the foot of two mountain ranges the Wasatch to the east and the Oquirrhs to the west. During August, hiking, rock climbing, and mountain biking are just minutes away. Daily sunshine, low humidity, and refreshing mountain breezes combine for a comfortable year-round climate.
Hotel
The full-service University Park Marriott is less than a 5 minute drive to the new John A. Moran Eye Center and the University of Utah, and a 10 minute drive to downtown. We have reserved a limited number of rooms at a discount rate of $99. These rooms may fill up quickly, so please register early. Please contact the hotel directly for reservations: University Park Marriott, 480 Wakara Way, Salt Lake City, Utah 84108, USA, phone 801-581-1000.
CME Credits
CME credit is being offered for the "Clinical Treatments" and the "Translational Research and the Patient" portions of the meeting only.
Accreditation
The University of Utah School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation
AMA PRA Category 1 Credit(s)TM will be awarded for a portion of the meeting. These sessions in the symposium we are offering CME credit for are "Clinical Treatments" session on August 2nd starting around 1:10-5:40 pm and "Translational Research and the Patient" session on August 3rd starting around 2:15-4:45 pm. Please be sure to let Julee know if you will be attending these presentations and wish to obtain AMA PRA Category
1 Credit(s)TM for it. There will be Self Reporting Attendance and Evaluation forms required at the end of the event for you to fill out if you wish to get the CME credit.
ADA
The University of Utah complies with the Americans with Disabilities Act by providing qualified individuals with disabilities access to University programs, services and activities. A request for accommodation can be made by calling 801-585-3723. Reasonable prior notice is required.
Faculty Disclosure
The University of Utah School of Medicine adheres to ACCME Standards regarding industry support of continuing medical education. Disclosure of faculty and commercial support relationships will be made known at the activity. Speakers are also expected to openly disclose intent to discuss any off-label, experimental, or investigational use of drugs, devices, or equipment in their presentations.
Responsibility:
The University of Utah School of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided by individuals who have been selected because of recognized expertise in the field.
Attendance:
The University of Utah School of Medicine requires that all participants self-report participation in the CME activity. Certificates of attendance, designating the maximum number of hours of participation, are distributed to each participant after the CME activity.
Objectives
- 1. Define new treatments for the photoreceptor degenerative diseases.
- 2. Describe the translational research trials and their impact on clinical practice.
- 3. Compare the relative merits of gene therapy, cell-based therapies, growth factor delivery, and electronic chips as clinical treatment modalities.
- 4. Critique the current progress in the interpretation and treatment of retinitis pigmentosa, age related macular degeneration and associated diseases
- 5. Identify institutions and clinicians that you can collaborate with in researching new treatments and cures.
Another objective is to review clinical implications for new treatments that are emerging for retinal degenerative diseases where ophthalmologists frequently do not have all the information to evaluate them and recommend whether their patients should join clinical trials. Another topic of review is a discussion of how to get laboratory science to the clinic, getting a realistic consensus view of progress, and how to speed it up.
With this type of event, it is possible to have schedule changes. The Moran Eye Center reserves the right to alter this schedule.